Can a benefit outlast treatment? Longevity Peptide
Longevity suggests added years. I’m drawn to an earlier question: how much upkeep does a useful change require?
Tesamorelin after withdrawal
The fat came back. In a 52-week tesamorelin program in adults with HIV and abdominal fat accumulation, the reduction in visceral fat—the fat around internal abdominal organs—was sustained during continued treatment. After treatment stopped, that fat reaccumulated.
The improvement initially absorbed me. The withdrawal result deserves equal billing. It tells us something practical about the kind of improvement being offered: its persistence depended on continued treatment in that study. A claim about longevity has to make room for that continuing work.
There is a legitimate benefit here. The same program reported a visceral-fat change of -18% at 52 weeks relative to baseline during continued treatment. Calling the change temporary would obscure the sustained result; calling it a lasting reset would obscure the return of fat. Both halves matter.
My starting concern at Longevity Peptide is the upkeep of a benefit, including the exposure that comes with maintaining it. The fuller account is on the tesamorelin study record and the tesamorelin page.
Observation periods
An NR trial ran for 8 weeks. An NMN trial in prediabetic, postmenopausal women ran for 10 weeks. Both concern materials the body can use to make NAD+. Those are useful stretches of observation, with very different ambitions from a lifetime.
The natural MOTS-c in blood supplied another kind of time record: researchers followed chronic hemodialysis patients for a median 26.5 months. Nobody was given MOTS-c in that cohort. The passage of time made a blood-level association observable; it supplied no evidence about how long a treatment benefit would last.
Semaglutide adds more direct clinical questions. SELECT counted cardiovascular deaths, nonfatal heart attacks and nonfatal strokes in adults with established cardiovascular disease and overweight or obesity, without diabetes. FLOW counted major kidney-disease events in people with type 2 diabetes and chronic kidney disease. Both reduced their combined outcomes versus placebo. The leap to extra years for healthy people remains untested by those results.
I prefer a benefit with its conditions still attached: who experienced it, what continued, and where observation ended. The comparison puts those conditions alongside one another.
Keeping a useful change
“Longevity peptide” sounds like a single category with a single destination. The substances gathered here have quite different jobs. NAD+ is a coenzyme rather than a peptide; cells use it in energy metabolism and consume it in repair and signaling reactions. MOTS-c is a peptide encoded in mitochondrial DNA. Tesamorelin and semaglutide are prescription medicines with specific approved uses.
I warm to experiments that measure something useful in living people. An honest limit leaves that interest intact. A continuing treatment can be worthwhile, and a short trial can be informative, without either settling how aging itself changes.
A deliberately mundane question runs through this: what would it take to hold on to this improvement? For tesamorelin, the withdrawal experiment gives part of an answer. For several other claims, the answer still needs a human experiment.